Opendata, web and dolomites

ExtremoChem

Chemically synthesised novel compounds for the stabilisation of biologics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ExtremoChem project word cloud

Explore the words cloud of the ExtremoChem project. It provides you a very rough idea of what is the project "ExtremoChem" about.

least    plan    stabilization    white    stabilise    direct    size    degrade    wasted    stages    small    market    once    purification    thermally    20    medical    biopharmaceutical    aggregation    sign    assuring    full    cells    biologics    biopharmaceuticals    biological    line    storage    protects       biologic    quality    revenues    commercial    reachable    issue    business    consisting    ph    agitation    interferins    industrial    molecules    feasible    synthetic    extremochem    compounds    humira    stressful    temperatures    biotechnology    suitable    preserve    material    rheumatoid    sound    restored    trial    cold    extraction    elaborate    organic    blood    volume    mabs    synthesises    arthritis    potency    share    lost    drugs    validation    effectiveness    obtain    otherwise    strict    stability    chain    proteins    neupogen    source    critical    prepare    safety    native    salinity    preventing    12    sensitive    degradation    carbons    savings    subject    tests    medicines    insulins    clinical    vaccines    lower   

Project "ExtremoChem" data sheet

The following table provides information about the project.

Coordinator
EXTREMOCHEM LDA 

Organization address
address: Estrada Municipal 528, 1
city: IGREJINHA
postcode: 7040-220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://extremochem.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXTREMOCHEM LDA PT (IGREJINHA) coordinator 50˙000.00

Map

 Project objective

Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source. Many of biopharmaceutical products are subject to very strict production, storage and distribution requirements in order to preserve effectiveness and safety. Biopharmaceuticals stability is a key issue in assuring that these medicines maintain their quality, safety and full potency. Once potency is lost, it cannot be restored, this means the biologic is wasted.

ExtremoChem synthesises a line of novel compounds consisting of synthetic small organic molecules, from 8 to 12 carbons, that are able to stabilise proteins and other biological material by preventing their degradation under stressful conditions, such as higher or lower temperatures, pH, salinity, agitation under which they would otherwise degrade. eXtremochem is suitable for a wide range of proteins such as mAbs, vaccines, insulins, interferins and etc. But ExtremoChem currently focuses on mAbs, such as Humira (for rheumatoid arthritis) & Neupogen (for growth of white blood cells), since they present a high value market. The eXtremochem compounds improve the stability of molecules in the most critical purification stages and protects biologics, preventing aggregation and increasing production volume by 20%. Furthermore, eXtremochem enables long-term storage of thermally sensitive biologics without the need for cold chain, thus bringing significant savings to biopharmaceuticals – 6.5% of their revenues.

The Phase 1 project will allow ExtremoChem to evaluate the medicines’ degradation under the presence of the small organic molecules through several stabilization tests, prepare a feasible industrial scale-up plan, plan a sound Ph 1 clinical trial, elaborate the business scale up, and size the reachable market and a reliable market share. Within the overall project, ExtremoChem aims to: obtain the clinical validation and sign at least one commercial agreement.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXTREMOCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXTREMOCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More